These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32691711)

  • 21. P53 and Ki-67 overexpression in gastroesophageal reflux disease--Barrett's esophagus and adenocarcinoma sequence.
    Binato M; Gurski RR; Fagundes RB; Meurer L; Edelweiss MI
    Dis Esophagus; 2009; 22(7):588-95. PubMed ID: 19302208
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Esophageal pepsin and proton pump synthesis in barrett's esophagus and esophageal adenocarcinoma.
    Samuels TL; Altman KW; Gould JC; Kindel T; Bosler M; MacKinnon A; Hagen CE; Johnston N
    Laryngoscope; 2019 Dec; 129(12):2687-2695. PubMed ID: 31046139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Matrix protein CCN1 is critical for prostate carcinoma cell proliferation and TRAIL-induced apoptosis.
    Franzen CA; Chen CC; Todorović V; Juric V; Monzon RI; Lau LF
    Mol Cancer Res; 2009 Jul; 7(7):1045-55. PubMed ID: 19584265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inducible nitric oxide synthase, nitrotyrosine and p53 mutations in the molecular pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Vaninetti NM; Geldenhuys L; Porter GA; Risch H; Hainaut P; Guernsey DL; Casson AG
    Mol Carcinog; 2008 Apr; 47(4):275-85. PubMed ID: 17849424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disintegrin and metalloproteinases (ADAMs) expression in gastroesophageal reflux disease and in esophageal adenocarcinoma.
    Kauttu T; Mustonen H; Vainionpää S; Krogerus L; Ilonen I; Räsänen J; Salo J; Puolakkainen P
    Clin Transl Oncol; 2017 Jan; 19(1):58-66. PubMed ID: 27026568
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Barrett Esophagus and Intramucosal Esophageal Adenocarcinoma.
    Rajendra S; Sharma P
    Hematol Oncol Clin North Am; 2017 Jun; 31(3):409-426. PubMed ID: 28501084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors regulating nuclear factor-kappa B activation in esophageal cancer cells: Role of bile acids and acid.
    Abdel-Latif MM; Inoue H; Kelleher D; Reynolds JV
    J Cancer Res Ther; 2016; 12(1):364-73. PubMed ID: 27072265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased p53 expression in the malignant transformation of Barrett's esophagus is accompanied by an upward shift of the proliferative compartment.
    Hritz I; Gyorffy H; Molnar B; Lakatos G; Sipos F; Pregun I; Juhasz M; Pronai L; Schaff Z; Tulassay Z; Herszenyi L
    Pathol Oncol Res; 2009 Jun; 15(2):183-92. PubMed ID: 18752044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overexpression of CCN1 in Het1A cells attenuates bile-induced esophageal metaplasia through suppressing non-canonical NFκB activation.
    Dang T; Meng X; Modak C; Wu J; Chang Z; Che N; Narvaez R; Chai J
    Cytokine; 2019 Apr; 116():61-69. PubMed ID: 30685604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
    Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
    J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene.
    Seta T; Imazeki F; Yokosuka O; Saisho H; Suzuki T; Koide Y; Isono K
    Dig Dis Sci; 1998 Feb; 43(2):279-89. PubMed ID: 9512119
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: synergism with sulindac-mediated inhibition of Bcl-x(L).
    Ravi R; Bedi A
    Cancer Res; 2002 Mar; 62(6):1583-7. PubMed ID: 11912124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BTG3 upregulation induces cell apoptosis and suppresses invasion in esophageal adenocarcinoma.
    Du Y; Liu P; Zang W; Wang Y; Chen X; Li M; Zhao G
    Mol Cell Biochem; 2015 Jun; 404(1-2):31-8. PubMed ID: 25701359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of the hexosamine biosynthetic pathway and pentose phosphate pathway in bile acid-induced cancer development.
    Munemoto M; Mukaisho KI; Miyashita T; Oyama K; Haba Y; Okamoto K; Kinoshita J; Ninomiya I; Fushida S; Taniura N; Sugihara H; Fujimura T
    Cancer Sci; 2019 Aug; 110(8):2408-2420. PubMed ID: 31215094
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of cyclin D1 and p53 and its correlation with proliferative activity in the spectrum of esophageal carcinomas induced after duodenal content reflux and 2,6-dimethylnitrosomorpholine administration in rats.
    Pera M; Fernandez PL; Pera M; Palacín A; Cardesa A; Dasenbrock C; Tillman T; Mohr U
    Carcinogenesis; 2001 Feb; 22(2):271-7. PubMed ID: 11181448
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis.
    Zhuang H; Jiang W; Cheng W; Qian K; Dong W; Cao L; Huang Q; Li S; Dou F; Chiu JF; Fang XX; Lu M; Hua ZC
    Lung Cancer; 2010 Apr; 68(1):27-38. PubMed ID: 19540014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The mutational status of p53 protein in gastric and esophageal adenocarcinoma cell lines predicts sensitivity to chemotherapeutic agents.
    Nabeya Y; Loganzo F; Maslak P; Lai L; de Oliveira AR; Schwartz GK; Blundell ML; Altorki NK; Kelsen DP; Albino AP
    Int J Cancer; 1995 Feb; 64(1):37-46. PubMed ID: 7665247
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High Content Imaging of Barrett's-Associated High-Grade Dysplasia Cells After siRNA Library Screening Reveals Acid-Responsive Regulators of Cellular Transitions.
    Phipps SM; Garry CE; Kamal S; Johnson JD; Gilmer J; Long A; Kelleher D; Duggan SP
    Cell Mol Gastroenterol Hepatol; 2020; 10(3):601-622. PubMed ID: 32416156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BAY61-3606 potentiates the anti-tumor effects of TRAIL against colon cancer through up-regulating DR4 and down-regulating NF-κB.
    Du J; Wang Y; Chen D; Ji G; Ma Q; Liao S; Zheng Y; Zhang J; Hou Y
    Cancer Lett; 2016 Dec; 383(2):145-153. PubMed ID: 27721019
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.
    Cheung WY; Zhai R; Kulke MH; Heist RS; Asomaning K; Ma C; Wang Z; Su L; Lanuti M; Tanabe KK; Christiani DC; Liu G
    Carcinogenesis; 2009 Aug; 30(8):1363-7. PubMed ID: 19520791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.